| Symbol | CLAZF |
|---|---|
| Name | CLARITAS PHARMACEUTICALS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 94903 United States CA 4040 Civic Center Drive Suite 200 |
| Telephone | +1 (888) 861-2008 |
| Fax | — |
| — | |
| Website | https://claritaspharma.com/ |
| Incorporation | CA |
| Incorporated On | 2014 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | BDO USA, LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Foreign Issuer - Not Listed on Foreign Exchange |
| CIK | 0001395961 |
| Description | Claritas Pharmaceuticals is developing R-107, a nitric oxide-releasing compound, designed to augment the bodys own natural production of nitric oxide. Nitric oxide is a molecule produced naturally by most cell types in the body to.open blood vessels, reduce blood pressure, combat infection and heal wounds. R-107 is a liquid, nitric oxide-releasing compound that is designed to supplement the bodys own natural production of nitric oxide. R-107 can be administered by several methods, including orally by capsule, or by injection, or by nasal spray, or topically in an ointment. Depending on the mode of administration, R-107 can target the many diseases, disorders, and injuries that the bodys own natural nitric oxide targets. Our scientific team has built a reputation for global leadership in the science of nitric oxide medicine. Claritas is headquartered in San Francisco, CA, and has laboratory facilities in Beverly, MA that are fully-equipped with state-of-the-art systems to carry out analytical, bioanalytical, and synthetic chemistry activities. Additional info from OTC: |
Expert Market symbol attribute type Security_Name was changed. Previous value: -. New value: CLARITAS PHARMACICLS INC.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: CLARITAS PHARMACICLS INC.
Read more